CZ304242B6 - Modifikovaná peptidová sloučenina - Google Patents

Modifikovaná peptidová sloučenina Download PDF

Info

Publication number
CZ304242B6
CZ304242B6 CZ2001-1323A CZ20011323A CZ304242B6 CZ 304242 B6 CZ304242 B6 CZ 304242B6 CZ 20011323 A CZ20011323 A CZ 20011323A CZ 304242 B6 CZ304242 B6 CZ 304242B6
Authority
CZ
Czechia
Prior art keywords
gly gly
leu
prt
artificial sequence
tyr
Prior art date
Application number
CZ2001-1323A
Other languages
Czech (cs)
English (en)
Inventor
Ulrich Feige
Chuan-Fa Liu
Janet Cheetham
Thomas Charles Boone
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26802505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ304242(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CZ304242B6 publication Critical patent/CZ304242B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
CZ2001-1323A 1998-10-23 1999-10-25 Modifikovaná peptidová sloučenina CZ304242B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10537198P 1998-10-23 1998-10-23
US09/428,082 US6660843B1 (en) 1998-10-23 1999-10-22 Modified peptides as therapeutic agents

Publications (1)

Publication Number Publication Date
CZ304242B6 true CZ304242B6 (cs) 2014-01-22

Family

ID=26802505

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2001-1323A CZ304242B6 (cs) 1998-10-23 1999-10-25 Modifikovaná peptidová sloučenina

Country Status (29)

Country Link
US (7) US6660843B1 (enExample)
EP (1) EP1144454B2 (enExample)
JP (9) JP2003512011A (enExample)
KR (3) KR100753303B1 (enExample)
CN (8) CN100384880C (enExample)
AT (1) ATE380828T1 (enExample)
AU (3) AU767725B2 (enExample)
BG (1) BG65721B1 (enExample)
BR (1) BR9914708A (enExample)
CA (1) CA2347131C (enExample)
CY (1) CY1107881T1 (enExample)
CZ (1) CZ304242B6 (enExample)
DE (1) DE69937752T3 (enExample)
DK (1) DK1144454T4 (enExample)
EA (1) EA005404B1 (enExample)
ES (1) ES2299278T5 (enExample)
HK (1) HK1042097B (enExample)
HU (1) HU229485B1 (enExample)
IL (2) IL142365A0 (enExample)
MX (1) MXPA01003873A (enExample)
NO (1) NO331733B1 (enExample)
NZ (2) NZ528882A (enExample)
PL (1) PL211164B1 (enExample)
PT (1) PT1144454E (enExample)
RS (1) RS51852B (enExample)
SI (1) SI1144454T2 (enExample)
SK (1) SK287037B6 (enExample)
WO (1) WO2000024782A2 (enExample)
ZA (1) ZA200102753B (enExample)

Families Citing this family (573)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
ME00238B (me) 1998-10-23 2011-02-10 Kirin Amgen Inc Mimičko vezivanje dimernog trombopoitetinskog peptida za mp1 receptor sa trombopoietičkom aktivnošću
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU2880400A (en) * 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
BR0008712A (pt) 1999-03-03 2001-12-26 Lilly Co Eli Complexos equinocandina/carboidrato
PT1582204E (pt) * 1999-03-03 2013-11-25 Lilly Co Eli Formulações farmacêuticas de equinocandina que contêm tensioactivos que formam micelas
WO2001001749A2 (en) 1999-07-02 2001-01-11 Genentech, Inc. FVIIa ANTAGONISTS
CA2373721C (en) 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
ATE407697T1 (de) * 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1274723A4 (en) * 1999-07-29 2003-10-01 Univ Johns Hopkins ACTIVATION OF PEPTIDE PRODRUGS BY hK2
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA02010324A (es) 2000-04-21 2003-04-25 Amgen Inc Derivados de peptidos apo-ai/aii.
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
AU2001259432B2 (en) * 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
WO2001087979A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
NZ522924A (en) * 2000-05-26 2004-12-24 Ortho Mcneil Pharm Inc Neuroprotective peptides
AU7522601A (en) * 2000-06-02 2001-12-11 Eidgenoess Tech Hochschule Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
WO2002020762A2 (en) * 2000-09-05 2002-03-14 Amgen Inc. Tnf receptor-like molecules and uses thereof
AU2003295623B2 (en) * 2000-12-05 2008-06-05 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
DE60136656D1 (de) 2000-12-05 2009-01-02 Alexion Pharma Inc Rationell entworfene Antikörper
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7622446B2 (en) * 2001-04-18 2009-11-24 The Open University Polypeptides, derivatives and uses thereof
US7491702B2 (en) * 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
MXPA03010210A (es) 2001-05-11 2004-03-10 Amgen Inc Peptidos y moleculas relacionadas que se enlazan a tall-1.
NO345566B1 (no) * 2001-06-26 2021-04-19 Amgen Inc OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav
MXPA04003057A (es) 2001-10-04 2005-06-20 Immunex Corp Proteina 4 de enlace ul16.
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030113270A1 (en) * 2001-12-14 2003-06-19 Clark Abbot F. Vasoactive intestinal peptides for glaucomatous retinopathy
US20030138975A1 (en) * 2001-12-20 2003-07-24 Kimberly-Clark Worldwide, Inc. Diagnostic signal amplification with proteinoid microspheres
US7056535B2 (en) * 2001-12-20 2006-06-06 Kimberly-Clark Worldwide, Inc. Triggered release from proteinoid microspheres
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
EP1497444B1 (en) 2002-03-27 2015-11-04 Immunex Corporation Methods for increasing polypeptide production
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2481074A1 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
AU2003280130B2 (en) * 2002-06-28 2009-06-11 Centocor, Inc. Mammalian CH1 deleted mimetibodies, compositions, methods and uses
EP1394180B1 (de) * 2002-08-06 2008-07-16 AplaGen GmbH Synthetische Mimetika von physiologischen Bindungsmolekülen
WO2004014951A2 (en) * 2002-08-06 2004-02-19 Aplagen Gmbh Binding molecules
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
RU2329274C2 (ru) * 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
MXPA05003057A (es) 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
AR042545A1 (es) * 2002-12-20 2005-06-22 Amgen Inc Agentes ligantes que inhiben la miostatina
US7125849B2 (en) * 2003-01-14 2006-10-24 The Scripps Research Institute Peptide-based angiogenesis inhibitors and methods of use thereof
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2004208865B2 (en) * 2003-02-06 2010-06-17 Merck Patent Gmbh Peptidic sulfonamides
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
WO2004108885A2 (en) * 2003-05-06 2004-12-16 Syntonix Pharmaceuticals, Inc. Fc chimeric proteins with anti-hiv drugs
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2558102T3 (es) * 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
WO2004100882A2 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
BRPI0411160A (pt) * 2003-05-12 2006-07-11 Affymax Inc novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
EA010015B1 (ru) * 2003-05-12 2008-06-30 Афимакс, Инк. Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
AP2042A (en) * 2003-05-12 2009-09-07 Affymax Inc Novel peptides that bind to the erythropoietin receptor
NZ543935A (en) * 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
CA2529997A1 (en) * 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh Novel surface protein (hbsag) variant of hepatitis b virus
EP2341067A1 (en) 2003-07-18 2011-07-06 Amgen, Inc Specific binding agents to hepatocyte growth factor
ES2383328T3 (es) 2003-07-25 2012-06-20 Amgen, Inc Métodos relacionados con LDCAM y CRTAM
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
DE602004023956D1 (de) 2003-08-18 2009-12-17 Univ California Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon
US8158589B2 (en) 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
WO2005081687A2 (en) * 2003-09-30 2005-09-09 Centocor, Inc. Human hinge core mimetibodies, compositions, methods and uses
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
RU2356909C2 (ru) * 2003-11-13 2009-05-27 Ханми Фарм. Инд. Ко., Лтд. Белковый комплекс, полученный с использованием фрагмента иммуноглобулина, и способ получения такого комплекса
US20110160440A1 (en) 2003-12-12 2011-06-30 Genencor International, Inc. Cab Molecules
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CN1929865B (zh) * 2004-03-11 2011-11-16 费森尤斯卡比德国有限公司 羟烷基淀粉和蛋白质的接合物
TWI417303B (zh) 2004-03-11 2013-12-01 Fresenius Kabi De Gmbh 經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
SI1729810T1 (sl) * 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab (Publ) Postopki za zmanjšanje agregacije IL-1RA
US20050222040A1 (en) * 2004-04-05 2005-10-06 Blm Group, Inc. Vertebrate peptide modulators of lipid metabolism
EP1735350B1 (en) 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept
JP2005309295A (ja) * 2004-04-26 2005-11-04 Nec Corp 光増幅素子、光増幅装置および光増幅システム
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
MX2007000216A (es) * 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
WO2006014567A2 (en) 2004-07-08 2006-02-09 Pneumrx, Inc. Pleural effusion treatment device, method and material
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
WO2007001332A2 (en) * 2004-08-04 2007-01-04 University Of Massachusetts Anti-pathogen immunoadhesins
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2006036834A2 (en) * 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
JP2008537874A (ja) * 2004-09-27 2008-10-02 セントカー・インコーポレーテツド ｓＲＡＧＥミメティボディ、組成物、方法および使用
AU2005305182A1 (en) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind BAFF and/or APRIL
CN101142234A (zh) * 2004-11-11 2008-03-12 阿费麦克斯公司 结合红细胞生成素受体的新肽
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US20070110760A1 (en) * 2005-01-14 2007-05-17 Monroe John G Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity
US8053415B2 (en) * 2005-01-21 2011-11-08 Washington University In St. Louis Compounds having RD targeting motifs
CN101238142B (zh) * 2005-02-18 2012-11-14 国立大学法人德岛大学 含聚氧化烯链的脂质衍生物及含有该衍生物的脂质膜结构体
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
US20060241040A1 (en) * 2005-04-06 2006-10-26 Alberto Visintin Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
DK1877102T3 (da) 2005-04-28 2014-07-21 Danisco Us Inc Tab-molekyler
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP3351269B1 (en) 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
WO2006136450A2 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
WO2007005608A2 (en) * 2005-06-30 2007-01-11 Abbott Laboratories Il-12/p40 binding proteins
CA2854576A1 (en) 2005-07-18 2007-01-25 Haichun Huang Human anti-b7rp1 neutralizing antibodies
DK2298815T3 (en) * 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
CA2915270C (en) 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CN101258164B (zh) 2005-08-16 2013-05-01 韩美科学株式会社 用于大量生产缺失起始甲硫氨酸残基的免疫球蛋白Fc区的方法
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP2535346B1 (en) * 2005-08-31 2017-08-02 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
KR100780405B1 (ko) * 2005-08-31 2007-11-28 재단법인서울대학교산학협력재단 알파 나선형 펩티드를 이용한 ｒｎａ 특이적 결합 펩티드탐색 방법
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
US20070134234A1 (en) * 2005-09-29 2007-06-14 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US8445642B1 (en) * 2005-10-13 2013-05-21 The United States Of America As Represented By The Secretary Of Agriculture Methods to differentiate protein conformers
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EA200801174A1 (ru) * 2005-10-24 2009-02-27 Сентокор, Инк. Антитела-миметики glp-2, полипептиды, композиции, способы и применения
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2006308870B2 (en) * 2005-10-31 2012-08-16 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
US20070149458A1 (en) * 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
WO2007067564A2 (en) 2005-12-08 2007-06-14 Amgen Inc. Improved host cells and culture methods
ATE517923T1 (de) 2005-12-12 2011-08-15 Hoffmann La Roche Antikörper gegen amyloid beta mit glykosilierung in der variablen region
US20090054763A1 (en) * 2006-01-19 2009-02-26 The Regents Of The University Of Michigan System and method for spectroscopic photoacoustic tomography
US9012605B2 (en) * 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20070179094A1 (en) 2006-01-31 2007-08-02 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
JP2009529917A (ja) 2006-03-22 2009-08-27 ヴァイラル ロジック システムズ テクノロジー コーポレーション 標的ポリペプチドの同定方法および免疫学的疾患の治療のためのその使用
CA2648035A1 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions or renal disease associated anemia
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
US10167332B2 (en) 2006-04-05 2019-01-01 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20100222554A1 (en) * 2006-04-11 2010-09-02 Thomas Weimer Method of Increasing the In Vivo Recovery of Therapeutic Polypeptides
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
JP2009537145A (ja) * 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
CA2662549C (en) 2006-09-08 2014-10-28 Amgen Inc. Il-1 family variants
KR20090060334A (ko) * 2006-09-08 2009-06-11 제넨테크, 인크. Ｗｎｔ 길항제 및 ｗｎｔ-매개 장애의 진단 및 치료에서의 이의 용도
CA2662701C (en) * 2006-09-08 2015-12-08 Abbott Laboratories Interleukin-13 binding proteins
US20140147441A1 (en) * 2006-09-12 2014-05-29 The General Hospital Corporation Compositions containing alpha-1-antitrypsin and methods for use
WO2008100288A2 (en) * 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
WO2008036763A2 (en) * 2006-09-20 2008-03-27 Pneumrx, Inc. Tissue adhesive compositions and methods thereof
US20100034194A1 (en) * 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
AU2007343796A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
US20080123083A1 (en) * 2006-11-29 2008-05-29 The Regents Of The University Of Michigan System and Method for Photoacoustic Guided Diffuse Optical Imaging
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
KR100888022B1 (ko) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
JP2010520855A (ja) 2007-01-31 2010-06-17 アフィーマックス・インコーポレイテッド 修飾基をポリペプチドおよびその他の高分子に結合するための窒素ベースのリンカー
CA2678001C (en) * 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
EP2152736B1 (en) 2007-05-03 2017-07-05 Lysomab GmbH Complement factor h-derived short consensus repeat-antibody constructs
MX2009012343A (es) * 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
AU2008262490B2 (en) 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
EP2165716B1 (en) * 2007-06-05 2014-11-12 Oriental Yeast Co., Ltd. Novel bone mass increasing agent
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
MX348799B (es) 2007-07-26 2017-06-29 Amgen Inc Enzimas aciltransferasa de lecitina-colesterol, modificadas.
CA2720628A1 (en) * 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
EA201070231A1 (ru) * 2007-08-09 2010-10-29 Синтоникс Фармасьютикалз, Инк. Иммуномодулирующие пептиды
AU2008289225A1 (en) * 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and Fc-fusion molecules using polycations
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US20100291086A1 (en) * 2007-09-11 2010-11-18 Christopher Hovens Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
US8383114B2 (en) 2007-09-27 2013-02-26 Amgen Inc. Pharmaceutical formulations
EP2207530A4 (en) * 2007-10-02 2013-09-11 Potentia Pharmaceuticals Inc DELAYED RELEASE OF COMPSTATIN ANALOG FROM GELEN
US7829735B2 (en) 2007-10-26 2010-11-09 Northwestern University Universal phosphoramidite for preparation of modified biomolecules and surfaces
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
DK2808343T3 (da) 2007-12-26 2019-08-19 Xencor Inc Fc-varianter med ændret binding til FcRn
US20140127200A1 (en) * 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
EP2803675A3 (en) 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
CN101518644B (zh) * 2008-02-26 2011-07-13 上海交通大学医学院附属第九人民医院 Ang-2及其基因在制药中的应用
EP2626080A3 (en) * 2008-02-27 2014-03-05 Novo Nordisk A/S Conjugated factor VIII molecules
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
RS51975B (sr) * 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
KR20160107299A (ko) 2008-05-09 2016-09-13 아비에 도이치란트 게엠베하 운트 콤파니 카게 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
WO2009142460A2 (en) * 2008-05-23 2009-11-26 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
NZ590358A (en) * 2008-07-23 2012-04-27 Hanmi Holdings Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
EP2168590A1 (en) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Antimicrobial peptides
US7982013B2 (en) 2008-09-26 2011-07-19 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
HUE032090T2 (en) 2008-11-26 2017-09-28 Amgen Inc Stabilized variants of activin IIB receptor
WO2010081095A2 (en) * 2009-01-12 2010-07-15 The Regents Of The University Of California Methods and compositions for inhibiting hepatitis c virus replication
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
EP2391652A4 (en) * 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
JP5980508B2 (ja) * 2009-03-11 2016-08-31 プロメディオール， インコーポレイテッド 自己免疫障害に対する処置方法
CA3018235C (en) 2009-03-20 2021-01-12 Amgen Inc. Carrier immunoglobulins and uses thereof
US20120018338A1 (en) 2009-03-30 2012-01-26 Hoffman-La Roche Inc. Method for avoiding glass fogging
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
UY38740A (es) 2009-05-05 2020-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
DK2443137T3 (en) 2009-06-15 2015-08-24 Biokine Therapeutics Ltd NOVEL chemokine-binding peptides capable of impeding the sequence for immunity, inflammation and cancer
AU2010262927A1 (en) 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
HUE041034T2 (hu) * 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
EP2445923B1 (en) 2009-06-22 2018-09-05 Amgen, Inc Refolding proteins using a chemically controlled redox state
MX2011013417A (es) 2009-06-25 2012-03-29 Amgen Inc Procesos de purificacion por captura para proteinas expresadas en un sistema no mamifero.
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
IT1395137B1 (it) * 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
SMT201700248T1 (it) 2009-11-02 2017-07-18 Univ Washington Composizioni terapeutiche di nucleasi e metodi
CA2780763A1 (en) 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
JP5876416B2 (ja) * 2009-11-13 2016-03-02 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用
TW201129379A (en) 2009-11-20 2011-09-01 Amgen Inc Anti-Orai1 antigen binding proteins and uses thereof
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
SG181563A1 (en) 2009-12-08 2012-07-30 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
US9150631B2 (en) * 2010-01-19 2015-10-06 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
CA2788175A1 (en) 2010-01-28 2011-08-04 Raptor Discoveries Inc. Method for treating liver disorders with receptor associated protein (rap) peptide-fucosidase inhibitor conjugates
JP2013519699A (ja) 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス 因子ｖｉｉｉ融合タンパク質
US20130171128A1 (en) 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
EP2542571B1 (en) 2010-03-03 2016-05-25 The University of British Columbia Oligomer-specific amyloid beta epitope and antibodies
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
JP2013523098A (ja) 2010-03-29 2013-06-17 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
AR081755A1 (es) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
EP2556086B1 (en) 2010-04-09 2015-03-04 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
AU2011239689A1 (en) 2010-04-15 2012-11-08 Amgen Inc. Human FGF receptor and beta-Klotho binding proteins
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
EP2569336A1 (en) 2010-05-14 2013-03-20 Amgen Inc. Enhanced death receptor agonists
SG185502A1 (en) 2010-05-14 2012-12-28 Abbvie Inc Il-1 binding proteins
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
US20110305670A1 (en) * 2010-06-10 2011-12-15 President And Fellows Of Harvard College Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
US8735548B2 (en) 2010-06-30 2014-05-27 Amgen Inc. Antibodies which bind to SCNN1A/TNFRSF1A fusion proteins and methods of use thereof
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
AU2011305306C1 (en) 2010-09-22 2016-02-18 Amgen Inc. Carrier immunoglobulins and uses thereof
BR112013007385B1 (pt) 2010-09-28 2022-07-26 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
CA2821976A1 (en) 2010-12-21 2012-09-13 Abbvie Inc. Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
WO2012102679A1 (en) 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
EP2681238A2 (en) 2011-02-28 2014-01-08 Istituto di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo- Ospedale di Alta Specializzazione E di Rilievo Apoptosis-inducing molecules and uses therefor
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
KR101954052B1 (ko) 2011-03-09 2019-03-06 체에스엘 베링 게엠베하 인공 표면과의 접촉을 포함하는 의료 시술에 투여하기 위한 인자 ｘｉｉ 억제제
HK1198173A1 (en) 2011-03-16 2015-03-13 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
WO2012138997A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
CN103608354B (zh) * 2011-04-25 2016-10-05 大鹏药品工业株式会社 含有pH-响应肽的纳米颗粒
SI2704737T1 (en) 2011-04-29 2018-06-29 University Of Washington Therapeutic nuclease compositions and methods
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
SI2718318T1 (sl) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina in le-te obsegajoča farmacevtska sestava za zdravljenje debelosti
ES2710356T3 (es) * 2011-06-17 2019-04-24 Hanmi Science Co Ltd Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
JP6069312B2 (ja) 2011-06-29 2017-02-01 アムジェン インコーポレイテッド 腎細胞癌の治療における生存の予測バイオマーカー
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
CN103930134B (zh) 2011-07-18 2016-12-21 阿茨生物股份有限公司 长效促黄体激素(lh)化合物
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EP3081937B1 (en) 2011-07-18 2019-11-13 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
MX347454B (es) 2011-07-22 2017-04-27 Csl Ltd Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
AU2012289433B2 (en) 2011-07-25 2017-07-27 Evive Biotechnology (Shanghai) Ltd Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases
US9605083B2 (en) 2011-08-16 2017-03-28 Emory University JAML specific binding agents, antibodies, and uses related thereto
DE202012012998U1 (de) 2011-08-31 2014-06-13 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
EP2751135A4 (en) * 2011-08-31 2015-06-03 Indi Molecular Inc VEGF SPECIFIC CAPTURING AGENTS, COMPOSITIONS CONTAINING SAME AND METHODS OF USE AND PRODUCTION THEREOF
CN103917458A (zh) 2011-09-02 2014-07-09 安姆根有限公司 药物产品和分析药物产品的光暴露的方法
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
PL2766397T3 (pl) 2011-10-11 2018-10-31 F.Hoffmann-La Roche Ag Ulepszone składanie przeciwciał bispecyficznych
UY34409A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf
SG11201401796SA (en) 2011-10-24 2014-10-30 Abbvie Inc Bispecific immunobinders directed against tnf and il-17
CN104136047B (zh) 2011-10-26 2018-02-06 安姆根有限公司 减少或消除由暴露于uv光而引起的蛋白质修饰和降解的方法
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN107459576A (zh) 2011-12-14 2017-12-12 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
BR112014015003A2 (pt) 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
WO2013096926A1 (en) 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
CN102558358A (zh) * 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
US10230943B2 (en) 2012-01-23 2019-03-12 Washington University Goggle imaging systems and methods
ES2676725T3 (es) 2012-01-27 2018-07-24 AbbVie Deutschland GmbH & Co. KG Composición y método para el diagnóstico y el tratamiento de enfermedades asociadas con la degeneración de las neuritas
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
RU2644341C2 (ru) 2012-02-10 2018-02-08 Дженентек, Инк. Одноцепочечные антитела и другие гетеромультимеры
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
WO2013126813A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX351993B (es) 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
MX350202B (es) 2012-03-28 2017-08-30 Amgen Inc Combinaciones de agonistas de receptores de muerte 5 (dr5).
BR112014026162A2 (pt) 2012-04-23 2017-10-03 Nrl Pharma Inc Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013167750A2 (en) 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
AU2013274347B2 (en) 2012-06-11 2018-03-08 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
CA2871880A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
EP2875046B2 (en) 2012-07-19 2025-04-30 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
CN110894231A (zh) * 2012-10-17 2020-03-20 康诺贝林伦瑙有限公司 免疫调节蛋白
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
BR112015009961B1 (pt) 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
TWI652071B (zh) 2012-11-06 2019-03-01 韓美藥品股份有限公司 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
ES2668045T3 (es) 2012-12-07 2018-05-16 Glycomimetics, Inc. Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas
US20160067347A1 (en) * 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
WO2014110503A1 (en) * 2013-01-11 2014-07-17 Case Western Reserve University Methods and compositions for treating cancer
KR102073748B1 (ko) 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
EA201591423A1 (ru) 2013-02-01 2016-01-29 Санта Мария Биотерапевтикс, Инк. Введение антитела к активину-а пациентам
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
CN114989289B (zh) * 2013-02-26 2024-10-01 韩美药品株式会社 新颖的胰岛素类似物及其用途
DK2964255T3 (da) 2013-03-08 2021-02-08 Csl Behring Gmbh Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
EP2966092A4 (en) 2013-03-08 2016-11-16 Taiho Pharmaceutical Co Ltd NOVEL PEPTIDE WITH 5 CONNECTED CTL EPITOPES
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
RU2692652C2 (ru) 2013-03-13 2019-06-25 Джензим Корпорейшн Слитые белки, содержащие связывающие pdgf и vegf части, и способы их применения
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
JP6581572B2 (ja) 2013-06-07 2019-09-25 デューク ユニバーシティ 補体因子ｈ阻害薬
JP2017501968A (ja) 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
JP6267792B2 (ja) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
AU2014293386B2 (en) 2013-07-25 2016-11-17 Novartis Ag Cyclic polypeptides for the treatment of heart failure
MX2016001021A (es) 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
MX380129B (es) 2013-09-08 2025-03-11 Pfizer Composiciones de neisseria meningitidis y sus metodos
PL3046933T3 (pl) * 2013-09-18 2019-08-30 Bcn Peptides, S.A. Analogi kortystatyny do leczenia chorób zapalnych i/lub immunologicznych
WO2015057820A2 (en) * 2013-10-15 2015-04-23 Roberts S Kenny Peptide constructs and well-defined aggregates thereof
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
ES2796301T3 (es) * 2013-10-21 2020-11-26 Taiho Pharmaceutical Co Ltd Nuevo péptido con cuatro epítopos CTL unidos
PL3063275T3 (pl) 2013-10-31 2020-03-31 Resolve Therapeutics, Llc Terapeutyczne fuzje nukleaza-albumina i sposoby
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
EP3091999B2 (en) 2014-01-09 2025-05-07 Hadasit Medical Research Services and Development Ltd. Improved cell compositions and methods for cancer therapy
WO2015138337A1 (en) 2014-03-09 2015-09-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
DK3129406T3 (en) * 2014-04-11 2019-04-01 Medimmune Llc CONJUGATED COMPOUNDS INCLUDING CYSTEIN MODIFIED ANTIBODIES
WO2015171822A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
EP3674314B8 (en) 2014-06-10 2023-07-12 Amgen Inc. Apelin polypeptides
WO2015191760A2 (en) 2014-06-10 2015-12-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
EP3157548B1 (en) 2014-06-18 2021-08-04 CSL Behring GmbH Therapy using a factor xii inhibitor in a neurotraumatic disorder
JP6676551B2 (ja) 2014-07-02 2020-04-08 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォンウィルブランド因子
WO2016014725A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
AU2015318008B2 (en) 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
MX377591B (es) 2014-10-15 2025-03-10 Amgen Inc Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas.
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AU2015371172B2 (en) * 2014-12-22 2021-05-13 Lanthiopep B.V. Novel methods for displaying cyclic peptides on bacteriophage particles
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
TW201639596A (zh) 2015-01-24 2016-11-16 艾伯維有限公司 用於治療牛皮癬性關節炎之組合物及方法
AU2016211242A1 (en) * 2015-01-30 2017-08-17 University Of Utah Research Foundation Dimeric collagen hybridizing peptides and methods of using
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
EP3265491A1 (en) 2015-03-03 2018-01-10 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
CN107428844A (zh) * 2015-03-05 2017-12-01 发展生物工程与基因技术的彼得和特劳德尔·恩格尔霍恩基金会 用于将肽呈递在细胞表面上的系统
US11215616B2 (en) 2015-04-10 2022-01-04 National Institutes Of Health (Nih), (Dhhs), U.S. Government Methods of determining patient populations amenable to immunomodulatory treatment of cancer
US10857229B2 (en) 2015-04-30 2020-12-08 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
US10806804B2 (en) 2015-05-06 2020-10-20 Washington University Compounds having RD targeting motifs and methods of use thereof
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
EP3763378A1 (en) 2015-08-06 2021-01-13 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
EP3350216A1 (en) 2015-09-15 2018-07-25 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3-BINDING POLYPEPTIDES
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
JP2018529729A (ja) 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド 胆汁酸障害の処置
IL257110B (en) 2015-10-02 2022-09-01 Hoffmann La Roche Bispecific antibodies specific against pd1 and tim3
US10975131B2 (en) 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
KR101826792B1 (ko) * 2015-10-29 2018-02-09 주식회사 와이바이오로직스 Dlk1의 세포 외 수용성 도메인을 유효성분으로 포함하는 지방간 또는 인슐린 저항성 증후군 예방 및 치료용 조성물
CN108472504A (zh) * 2015-12-15 2018-08-31 萨勒普塔医疗公司 肽寡核苷酸缀合物
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
EP3741432B1 (en) 2015-12-17 2023-05-10 AlonBio Ltd. Quinolin-2,4-one derivatives for inhibiting chemokine activity
US10646465B2 (en) 2015-12-17 2020-05-12 Biokine Therapeutics Ltd. Small molecules against cancer
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
ES2909573T3 (es) 2016-01-07 2022-05-09 CSL Behring Lengnau AG Factor de von Willebrand truncado mutado
KR20180132831A (ko) 2016-04-06 2018-12-12 시에스엘 리미티드 죽상동맥경화증의 치료 방법
KR101975743B1 (ko) * 2016-04-07 2019-05-09 한양대학교 에리카산학협력단 신혈관 생성 억제를 위한 혈관내피성장인자 수용체 타겟팅 펩타이드-엘라스틴 융합 폴리펩타이드 및 자가조립 나노구조체
US20190145962A1 (en) * 2016-04-14 2019-05-16 Tao Health Life Pharma Co., Ltd. Peptide for inhibiting binding of amylospheroids (aspd), and evaluation and screening method
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
MY199278A (en) 2016-06-08 2023-10-24 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates
CN119120423A (zh) 2016-07-01 2024-12-13 分解治疗有限责任公司 优化的二核酸酶融合体和方法
WO2018018011A2 (en) 2016-07-22 2018-01-25 Amgen Inc. Methods of purifying fc-containing proteins
US20190264197A1 (en) * 2016-07-27 2019-08-29 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
US11459401B2 (en) 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
US11041014B2 (en) 2016-10-28 2021-06-22 S & K Biopharma, Inc. Lactoferrin/albumin fusion protein and production method therefor
DK3538134T3 (da) 2016-11-11 2022-02-07 CSL Behring Lengnau AG Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
SG11201903950UA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
JP7274417B2 (ja) 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド ４－１ｂｂ結合タンパク質及びその使用
WO2018102777A1 (en) * 2016-12-01 2018-06-07 University Of South Florida Peptibodies, compositions thereof, and methods of treating atrial fibrillation
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
IL267733B2 (en) 2017-01-31 2023-10-01 Pfizer Neisseria meningitidis compositions and methods thereof
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
KR102461885B1 (ko) * 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
EP4516809A3 (en) 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
US11141466B2 (en) 2017-06-22 2021-10-12 CSL Behring Lengnau AG Modulation of FVIII immunogenicity by truncated VWF
WO2019016402A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
BR112020001367A2 (pt) 2017-07-26 2020-08-11 Janssen Pharmaceutica N.V. métodos de proteção da integridade vascular induzida por terapia de radiação direcionada
WO2019028012A2 (en) 2017-07-31 2019-02-07 Dana-Farber Cancer Institute, Inc. METHODS OF USING PEMBROLIZUMAB AND TREBANANIB
SI3661562T1 (sl) 2017-08-04 2025-01-31 Amgen Inc. Postopek konjugiranja CYS-MABS
JP2020530453A (ja) 2017-08-09 2020-10-22 マサチューセッツ インスティテュート オブ テクノロジー アルブミン結合ペプチド結合体及びその方法
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
ES2887046T3 (es) 2017-08-17 2021-12-21 Just Evotec Biologics Inc Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes
EP3672986A1 (en) 2017-08-22 2020-07-01 Sanabio, LLC Soluble interferon receptors and uses thereof
WO2019126371A1 (en) 2017-12-19 2019-06-27 Massachusetts Institute Of Technology Antigen-adjuvant coupling reagents and methods of use
WO2019190293A1 (ko) * 2018-03-30 2019-10-03 한미약품 주식회사 뇌 표적 지속성 단백질 결합체, 이의 제조 방법, 및 이를 포함하는 조성물
US12251447B2 (en) 2018-06-29 2025-03-18 Taiho Pharmaceutical Co., Ltd. Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer
PT3870957T (pt) 2018-10-23 2025-09-01 Amgen Inc Calibração automática e manutenção automática de modelos espetroscópicos para previsões em tempo real
US20210395751A1 (en) 2018-10-31 2021-12-23 The University Of Sydney Compositions and methods for treating viral infections
CA3124352A1 (en) 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
JP2022516574A (ja) * 2019-01-07 2022-02-28 センナ バイオサイエンシーズ インク． 新規ペプチドとその使用
JP2022523295A (ja) 2019-01-25 2022-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 発疱剤および苛性ガスの毒性作用を緩和する方法
MA54820A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
US20200237872A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
AU2020223376A1 (en) 2019-02-15 2021-07-22 Just - Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
EP3941580A1 (en) 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
CN114144433A (zh) 2019-03-22 2022-03-04 反射制药有限公司 用于目标蛋白的多价d-肽化合物
CN114096524B (zh) 2019-05-15 2025-03-04 阿龙拜欧有限公司 用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子
KR20220009984A (ko) 2019-05-17 2022-01-25 유니베르시태트 취리히 출혈성 뇌졸중 후 2차 신경학적 이상 반응을 치료하는데 사용하기 위한 합토글로빈
EA202193322A1 (ru) 2019-05-30 2022-03-10 Эмджен Инк. Конструирование шарнирной области для управления димеризацией антител
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
AU2020304671A1 (en) 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
US20220389082A1 (en) 2019-07-04 2022-12-08 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
WO2021030488A1 (en) 2019-08-12 2021-02-18 Bienvenue David Leonard 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
EP4055060B1 (en) 2019-11-08 2025-07-09 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
JP7680442B2 (ja) 2019-11-11 2025-05-20 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド
US11712482B2 (en) 2019-12-13 2023-08-01 Washington University Near infrared fluorescent dyes, formulations and related methods
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules
JP2023512454A (ja) 2020-01-13 2023-03-27 アプティーボ リサーチ アンド デベロップメント エルエルシー タンパク質治療のための製剤
WO2021158469A1 (en) 2020-02-03 2021-08-12 Amgen Inc. Multivariate bracketing approach for sterile filter validation
AU2020432156A1 (en) * 2020-02-28 2022-09-15 Mannin Research Inc. Chimeric fusions between C4-binding protein C-terminal segment and Angiopoietin-1 fibrinogen-like domain as Angiopoietin mimetics and Tie2 agonists to treat vascular diseases
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
AU2021278935A1 (en) 2020-05-26 2022-12-08 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins
US20230322955A1 (en) 2020-08-20 2023-10-12 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
EP4225786A2 (en) 2020-10-07 2023-08-16 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
WO2022103773A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
JP2023551193A (ja) 2020-11-20 2023-12-07 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 抗体関連型拒絶反応を処置するための方法
IL303328A (en) 2020-12-01 2023-07-01 Aptevo Res & Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
HRP20251064T1 (hr) 2020-12-18 2025-11-07 Richter Gedeon Nyrt. Metode za pročišćavanje ponovno savijenog fc-peptidnog fuzionog proteina
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2024504822A (ja) 2021-02-01 2024-02-01 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 出血性脳卒中後の有害な二次神経学的転帰を処置または予防する方法
JP2024515301A (ja) 2021-04-20 2024-04-08 アムジエン・インコーポレーテツド 多重特異性及び一価のｉｇｇ分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
CN117321074A (zh) 2021-05-07 2023-12-29 瑞士杰特贝林生物制品有限公司 用于产生重组触珠蛋白(Hp)β链的表达系统
CA3219832A1 (en) 2021-05-21 2022-11-24 Fatih Uckun Dosing regimens for protein therapeutics
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
US20250026838A1 (en) 2021-07-13 2025-01-23 Truebinding, Inc. Methods of preventing protein aggregation
US20230104658A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica Nv Methods of increasing progenitor cell production
UY39981A (es) 2021-10-14 2023-07-31 Teneobio Inc Proteínas de unión a la mesotelina y usos de las mismas
AU2022379497A1 (en) 2021-10-27 2024-05-02 Amgen Inc. Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy
AU2022388722A1 (en) 2021-11-09 2024-05-23 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
EP4490202A1 (en) 2022-03-11 2025-01-15 University of Rochester Cyclopeptibodies and uses thereof
EP4476356A1 (en) 2022-03-24 2024-12-18 Richter Gedeon Nyrt. Method for the manufacture of biopharmaceuticals
AU2023312905A1 (en) 2022-07-27 2025-01-16 Teneobio, Inc. Mesothelin binding proteins and uses thereof
TW202423475A (zh) 2022-09-02 2024-06-16 瑞士商Ｃｓｌ貝林股份有限公司 用於治療或預防過度勃起反應或勃起功能障礙之血紅素結合蛋白
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure
CN120584137A (zh) 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途
EP4669669A1 (en) 2023-02-21 2025-12-31 Teneobio, Inc. C-KIT BINDING PROTEINS, CHIMERIC ANTIGENIC RECEPTORS AND THEIR USES
AU2024305352A1 (en) 2023-06-12 2025-12-04 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
WO2025037108A2 (en) 2023-08-15 2025-02-20 Board Of Trustees Of The Leland Stanford Junior University Modified thrombopoietin
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
CN117986346B (zh) * 2024-04-07 2024-07-26 中国人民解放军军事科学院军事医学研究院 一种tpo模拟肽及其应用
WO2025257801A1 (en) 2024-06-13 2025-12-18 CSL Innovation Pty Ltd Heme-binding protein for the treatment of ischemia-reperfusion injury (iri)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
WO1996018412A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
WO1997024137A1 (en) * 1995-12-28 1997-07-10 Tanox Biosystems, Inc. HYBRID WITH INTERFERON-α AND AN IMMUNOGLOBULIN Fc LINKED THROUGH A NON-IMMUNOGENIC PEPTIDE
WO1997034631A1 (en) * 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998028427A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
EP1144454A2 (en) * 1998-10-23 2001-10-17 Amgen Inc. Modified peptides as therapeutic agents

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
IN150740B (enExample) 1978-11-24 1982-12-04 Hoffmann La Roche
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4760067A (en) 1979-08-15 1988-07-26 Merck & Co., Inc. Allylsulfoxide enzyme inhibitors
EP0040506B1 (en) 1980-05-21 1986-08-20 Teijin Limited Reactive polymer and process for the preparation thereof
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
JPH0751511B2 (ja) 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4966888A (en) 1985-07-08 1990-10-30 Cornell Research Foundation, Inc. hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4522750A (en) 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE470099B (sv) 1984-05-17 1993-11-08 Jerker Porath Sulfonaktiverade tioeteradsorbenter för separation av t ex protein
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4670563A (en) 1984-06-20 1987-06-02 Sanofi Imidazolides as intermediates for the synthesis of cytotoxic conjugates
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4675285A (en) 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
SE454885B (sv) 1984-10-19 1988-06-06 Exploaterings Ab Tbf Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS62185029A (ja) 1986-02-07 1987-08-13 Ajinomoto Co Inc 修飾インタ−ロイキン−２
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
IL80005A (en) 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4965271A (en) 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5359032A (en) 1987-08-26 1994-10-25 Biogen Inc. Interkeukin-1 inhibitor
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL90339A (en) 1989-05-18 1996-10-16 Yeda Res & Dev Anti-cytotoxic protein and its purification
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
GB8806339D0 (en) 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
JPH0240399A (ja) 1988-07-27 1990-02-09 Takeda Chem Ind Ltd 線維芽細胞増殖因子ムテインの複合体あるいは組成物
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
GB8824592D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Purification process
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
JPH04502011A (ja) 1988-11-23 1992-04-09 ジェネンテク，インコーポレイテッド ポリペプチド誘導体
EP1201757A3 (en) 1988-12-22 2002-09-11 Genentech, Inc. Method for preparing water soluble polypeptides
FI913049A7 (fi) 1988-12-22 1991-06-20 Xoma Corp Estyneitä kytkentäaineita ja menetelmiä
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5216131A (en) 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
CA2011450C (en) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
EP0386289A1 (en) 1989-03-07 1990-09-12 Taniguchi, Tadatsugu, Dr. Recombinant interleukin-2 receptor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
EP0398327B2 (en) 1989-05-18 2013-02-20 Yeda Research And Development Co., Ltd. Tumor necrosis factor binding protein II, its purification and antibodies thereto
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
CA2485553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation Tumor necrosis factor - .alpha. and - .beta. receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
AU651955B2 (en) 1989-11-29 1994-08-11 Amgen, Inc. Production of recombinant human interleukin-1 inhibitor
ATE128184T1 (de) 1989-12-13 1995-10-15 Yeda Res & Dev Expression des rekombinanten tumor-nekrosisfaktor-bindungsproteins i (tbp-i).
WO1991011497A1 (de) † 1990-01-23 1991-08-08 MERCK Patent Gesellschaft mit beschränkter Haftung Flüssigkristallines medium
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
EP0544815A1 (en) 1990-07-17 1993-06-09 The Board Of Regents Of The University Of Oklahoma Peptides from the GMP-140 lectinbindingdomain and selectin binding ligands on carbonhydrates
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
AU657483B2 (en) 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
DE69133235T2 (de) 1990-08-31 2003-11-20 The Regents Of The University Of Minnesota, Minneapolis Verfahren zur Herstellung von Harzen für die Feststoff-Peptidsynthese
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0567566B2 (en) 1991-01-18 2007-07-04 Amgen Inc., Methods for treating tumor necrosis factor mediated diseases
JPH06508985A (ja) 1991-02-27 1994-10-13 クリエイティブ　バイオモレキュルズ　インコーポレイテッド 富セリンペプチドリンカー
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
ES2094920T3 (es) 1991-07-04 1997-02-01 Immunodex K S Reactivos y conjugados solubles en agua a base de polimeros que comprenden restos derivados de divinil sulfona.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5569779A (en) 1991-12-23 1996-10-29 Albemarle Corporation Polyfunctional michael addition products
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
WO1993022332A2 (en) † 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ES2252732T3 (es) 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
EP0648239A4 (en) 1992-07-02 1995-09-27 Collagen Corp BIOCOMPATIBLE POLYMERIC CONJUGATES.
WO1994004689A1 (en) * 1992-08-14 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant toxin with increased half-life
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
DE69334287D1 (de) 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
NZ247231A (en) * 1993-03-23 1994-10-26 Holyoake Ind Ltd Diffuser for air conditioning system; outlet air direction thermostatically controlled
EP0622394A1 (en) 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use
EP1004312A1 (en) 1993-07-30 2000-05-31 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5998172A (en) † 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
BR9408534A (pt) 1994-02-14 1997-08-05 Zymogenetics Inc Proteína isolada molécula de polinucleotídeos e de dna isolada vetor de expressão célula cultivada mam'fero não humano composição farmacêutica anticorpo sonda e processos para produzir uma proteina hematopoiética para estimular a produção de plaquetas em um mamifero e a proliferação celular para detectar em uma mistura de moléculas de dna uma molécula de dna e para purificar trombopoietina
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
DE69503849T2 (de) 1994-03-31 1999-04-01 Amgen Inc., Thousand Oaks, Calif. Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten
KR100257466B1 (ko) † 1994-05-06 2000-07-01 레지날드 쇼트버그 에스. 안토니우스-소도 Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체
US6184205B1 (en) † 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU693478B2 (en) 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
AU700605B2 (en) 1994-12-07 1999-01-07 Bionebraska, Inc. Production of peptides using recombinant fusion protein constructs
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
WO1996023899A1 (en) 1995-02-01 1996-08-08 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
YU34196A (sh) 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
AR003431A1 (es) 1995-06-07 1998-08-05 Glaxo Group Ltd Peptidos compuestos que se ligan al receptor de trombopoietina.
IL118524A (en) 1995-06-19 2004-02-19 Akzo Nobel Nv Peptides and pharmaceutical preparations containing them useful in the treatment of peptide tolerance
US5955574A (en) † 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
WO1997008553A1 (en) 1995-08-22 1997-03-06 The Regents Of The University Of California Targeting of proteins to the cell wall of gram-positive bacteria
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
EA200000825A1 (ru) 1996-02-09 2001-02-26 Амген Инк. Композиция, включающая ингибитор il-1 и полимер, контролирующий высвобождение
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
US5798246A (en) 1996-03-25 1998-08-25 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase
AU2597897A (en) 1996-03-28 1997-10-17 Brigham And Women's Hospital Peptide ligands of the urokinase receptor
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1997043316A1 (en) † 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
DE69737229T2 (de) 1996-06-07 2008-01-31 Takeda Pharmaceutical Co. Ltd. Peptid mit cortistatin- oder somatostatin-aktivität, verfahren zu dessen herstellung und dessen verwendungen
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE69734887T2 (de) 1996-09-10 2006-08-24 The Burnham Institute, La Jolla Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
AU4474497A (en) 1996-10-08 1998-05-05 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
US5958703A (en) * 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
WO1998033812A1 (en) 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
CN1202862C (zh) 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
EP1012292A1 (en) 1997-06-06 2000-06-28 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
JP2002511885A (ja) 1997-07-24 2002-04-16 ザ パーキン―エルマー コーポレーション 脂質膜を横切る輸送のための膜透過性構築物
US6238667B1 (en) 1997-09-19 2001-05-29 Heinz Kohler Method of affinity cross-linking biologically active immunogenic peptides to antibodies
CA2306246A1 (en) 1997-10-06 1999-04-15 Millennium Pharmaceuticals, Inc. Signal peptide containing proteins and uses therefor
BR9814817A (pt) 1997-10-10 2002-01-08 Cytovia Inc Inibidores de apoptose de dipeptìdio e o uso dos mesmos
DE69812727D1 (de) 1997-11-07 2003-04-30 Conjuchem Inc Opioid-konjugate mit endogenen Trägerproteinen
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
ME00238B (me) 1998-10-23 2011-02-10 Kirin Amgen Inc Mimičko vezivanje dimernog trombopoitetinskog peptida za mp1 receptor sa trombopoietičkom aktivnošću
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
AU2880400A (en) * 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
WO2000059530A1 (en) 1999-04-02 2000-10-12 Immunex Corporation Use of soluble tumor necrosis factor receptor for treatment heart failure
IL147270A0 (en) † 1999-07-02 2002-08-14 Genentech Inc Fusion peptides comprising a peptide ligand domain and a multimerization domain
CA2373721C (en) † 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
US20020160416A1 (en) * 2000-02-11 2002-10-31 Boyle William J. Receptor from TNF family
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
KR20050033563A (ko) 2002-06-28 2005-04-12 센토코 인코포레이티드 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
AU2003280130B2 (en) 2002-06-28 2009-06-11 Centocor, Inc. Mammalian CH1 deleted mimetibodies, compositions, methods and uses
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2006002854A2 (en) * 2004-06-25 2006-01-12 Licentia, Ltd. Tie receptor and tie ligand materials and methods for modulating female fertility
WO2006068953A2 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
WO1996018412A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
WO1997024137A1 (en) * 1995-12-28 1997-07-10 Tanox Biosystems, Inc. HYBRID WITH INTERFERON-α AND AN IMMUNOGLOBULIN Fc LINKED THROUGH A NON-IMMUNOGENIC PEPTIDE
WO1997034631A1 (en) * 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998028427A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
EP1144454A2 (en) * 1998-10-23 2001-10-17 Amgen Inc. Modified peptides as therapeutic agents

Also Published As

Publication number Publication date
KR20070050977A (ko) 2007-05-16
HK1090932A1 (en) 2007-01-05
CN1908014A (zh) 2007-02-07
WO2000024782A2 (en) 2000-05-04
CN1721447A (zh) 2006-01-18
HUP0203506A3 (en) 2012-09-28
CY1107881T1 (el) 2013-06-19
KR100753305B1 (ko) 2007-08-29
CN100384879C (zh) 2008-04-30
ZA200102753B (en) 2002-06-11
US20040071712A1 (en) 2004-04-15
JP2007089586A (ja) 2007-04-12
SK287037B6 (sk) 2009-10-07
CN1746189A (zh) 2006-03-15
JP2007091746A (ja) 2007-04-12
KR100753303B1 (ko) 2007-08-29
SI1144454T1 (sl) 2008-04-30
US20070049532A1 (en) 2007-03-01
CN1781946A (zh) 2006-06-07
BR9914708A (pt) 2002-07-16
ATE380828T1 (de) 2007-12-15
HUP0203506A2 (hu) 2003-02-28
EP1144454B1 (en) 2007-12-12
US7169905B2 (en) 2007-01-30
CN1781947A (zh) 2006-06-07
AU2004200690C1 (en) 2009-04-09
DK1144454T3 (da) 2008-05-05
HK1042097B (en) 2008-04-03
JP2007105044A (ja) 2007-04-26
US20040087778A1 (en) 2004-05-06
BG65721B1 (bg) 2009-08-31
US7186810B2 (en) 2007-03-06
WO2000024782A3 (en) 2002-06-06
CN100384880C (zh) 2008-04-30
KR100753304B1 (ko) 2007-08-29
AU2004200687C1 (en) 2009-03-26
CN1331701A (zh) 2002-01-16
CA2347131C (en) 2012-11-27
EA005404B1 (ru) 2005-02-24
NO20011963D0 (no) 2001-04-20
SK5252001A3 (en) 2002-12-03
EP1144454B2 (en) 2012-12-12
US7166707B2 (en) 2007-01-23
US20040053845A1 (en) 2004-03-18
US6660843B1 (en) 2003-12-09
HK1042097A1 (en) 2002-08-02
EA200100464A1 (ru) 2002-10-31
US20040044188A1 (en) 2004-03-04
JP2007084555A (ja) 2007-04-05
BG105461A (en) 2003-04-30
DE69937752T2 (de) 2008-12-24
JP2007084558A (ja) 2007-04-05
MXPA01003873A (es) 2003-10-14
DE69937752T3 (de) 2013-02-28
CN1310948C (zh) 2007-04-18
KR20070050978A (ko) 2007-05-16
CA2347131A1 (en) 2000-05-04
AU2004200690A1 (en) 2004-03-18
NO331733B1 (no) 2012-03-12
KR20010099706A (ko) 2001-11-09
AU2004200687A1 (en) 2004-03-18
US20040057953A1 (en) 2004-03-25
ES2299278T3 (es) 2008-05-16
NZ510888A (en) 2004-01-30
NO20011963L (no) 2001-06-21
AU1232200A (en) 2000-05-15
RS51852B (sr) 2012-02-29
AU2004200687B2 (en) 2007-05-10
DK1144454T4 (da) 2013-01-14
YU25901A (sh) 2005-07-19
JP2007091747A (ja) 2007-04-12
US7189827B2 (en) 2007-03-13
NZ528882A (en) 2005-06-24
ES2299278T5 (es) 2013-04-03
PL366080A1 (en) 2005-01-24
AU2004200690B2 (en) 2007-05-10
EP1144454A2 (en) 2001-10-17
AU767725B2 (en) 2003-11-20
PT1144454E (pt) 2008-02-08
PL211164B1 (pl) 2012-04-30
DE69937752D1 (de) 2008-01-24
JP2007084556A (ja) 2007-04-05
CN1781945A (zh) 2006-06-07
IL142365A (en) 2013-02-28
CN1746190A (zh) 2006-03-15
HU229485B1 (en) 2014-01-28
JP2007084557A (ja) 2007-04-05
SI1144454T2 (sl) 2013-04-30
IL142365A0 (en) 2002-03-10
JP2003512011A (ja) 2003-04-02
AU767725C (en) 2000-05-15

Similar Documents

Publication Publication Date Title
CZ304242B6 (cs) Modifikovaná peptidová sloučenina
AU2001259432A1 (en) Modified peptides, comprising an Fc domain, as therapeutic agents
WO2001083525A2 (en) Modified peptides, comprising an fc domain, as therapeutic agents
MXPA02010351A (es) Antagonistas de integrina/adhesion.
AU2004200691C1 (en) Modified peptides as therapeutic agents
HK1090932B (en) Modified peptides as therapeutic agents
AU2004231208A1 (en) Modified peptides as therapeutic agents

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20141025